The Real-World Impact of CAR T-Cell Therapy in Large B-Cell Lymphoma - Episode 4

Understanding Malignancy Risks With the Use of CAR T-cell Therapies

,

Miguel-Angel Perales, MD, shares background on the unique design of a real-world analysis of liso-cel in LBCL in which he and his co-investigators prospectively collected retrospective data.

EP. 1: The Expanding Utility of CAR T-Cell Therapy in LBCL
EP. 2: Sequencing With CAR T-Cell Therapy for LBCL
EP. 3: CAR T-Cell Therapy as a Second-Line Treatment for LBCL
Now Viewing
EP. 4: Understanding Malignancy Risks With the Use of CAR T-cell Therapies
EP. 5: Real World Findings for Liso-Cel in LBCL From the Cell Therapy Consortium
EP. 6: Expert Perspective on Real-World Follow-Up Analyses of Liso-Cel in LBCL
EP. 7: The Impact of Real-World Analyses in the Utilization of CAR T-Cell Therapy in LBCL
EP. 8: Bridging Therapy With CAR T-Cell Therapy in LBCL
EP. 9: The Future of CAR T-Cell Therapy in LBCL
EP. 10: Back to the Bench: Exploring the Potential of CAR T-Cell Therapy in Oncology

Related Content:

The Real-World Impact of CAR T-Cell Therapy in Large B-Cell LymphomaOncLive News Network®Hematologic OncologyCAR T-cell Therapy
Tailor-Made for a Lifelong Pursuit of Precision in Cancer Care
Dr Ip on Comparative Findings Between CAR T-Cell Therapies in LBCL
Venetoclax Plus PegC May Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML